Germany’s Federal Cartel Office approved Merck KGaA’s acquisition of Bio-Techne Corp. This regulatory clearance removes a major obstacle for the pending transaction. The companies expect the deal to close in late 2026 or early 2027.
Wells Fargo downgraded Bio-Techne stock to Equal Weight from Overweight. Analysts cited limited visibility into management plans during the pre-merger quiet period. The bank simultaneously raised its price target for the shares to $73.